Here are five points:
1. Zacks currently has a $38 price target on the stock.
2. Smith & Nephew has a consensus rating of “hold” and a consensus target price of $39.25 from all the brokerages covering the firm.
3. The company’s stock has a 50-day moving average of $32.91 and a 200-day moving average of $33.54.
4. Smith & Nephew has a one-year low of $30.23 and a one-year high of $37.84.
5. The stock has a market cap of $15.2 billion.
More articles on devices:
Rush Health partners with United Airlines to provide orthopedic, spine procedures: 4 observations
Expanding Orthopedics appoints Dale Binke as VP: 3 things to know
EOS imaging’s spineEOS receives FDA approval: 4 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
